Lifeboat Foundation

If used to make non-heritable genetic changes, CRISPR gene-editing technology holds tremendous promise for treating or curing a wide range of devastating disorders, including sickle cell disease, vision loss, and muscular dystrophy. Early efforts to deliver CRISPR-based therapies to affected tissues in a patient’s body typically have involved packing the gene-editing tools into viral vectors, which may cause unwanted immune reactions and other adverse effects.

Now, NIH-supported researchers have developed an alternative CRISPR delivery system: nanocapsules. Not only do these tiny, synthetic capsules appear to pose a lower risk of side effects, they can be precisely customized to deliver their gene-editing payloads to many different types of cells or tissues in the body, which can be extremely tough to do with a virus. Another advantage of these gene-editing nanocapsules is that they can be freeze-dried into a powder that’s easier than viral systems to transport, store, and administer at different doses.

In findings published in Nature Nanotechnology [1], researchers, led by Shaoqin Gong and Krishanu Saha, University of Wisconsin-Madison, developed the nanocapsules with specific design criteria in mind. They would need to be extremely small, about the size of a small virus, for easy entry into cells. Their surface would need to be adaptable for targeting different cell types. They also had to be highly stable in the bloodstream and yet easily degraded to release their contents once inside a cell.

When it comes to finding new treatments for cancer scientitists have been focusing on an anti-cancer agent known as Small interfering ribonucleic acid (siRNA). But getting this agent to cancer cells has been a challenge.

Scientists have developed a platform using nanoparticles to send a cancer-fighting agent to cells.

Scientists from the University of Cambridge have developed a platform that uses nanoparticles known as metal-organic frameworks to deliver a promising anti-cancer agent to cells.

Research led by Dr. David Fairen-Jimenez, from the Cambridge Department of Chemical Engineering and Biotechnology, indicates metal-organic frameworks (MOFs) could present a viable platform for delivering a potent anti-cancer agent, known as siRNA, to cells.

Small interfering ribonucleic acid (siRNA), has the potential to inhibit overexpressed cancer-causing genes, and has become an increasing focus for scientists on the hunt for new cancer treatments.

The replacement of animals as test subjects is one step closer to reality with the successful testing of multi-organ “human-on-a-chip” models to recapitulate the 28-day experiments typically used in animals to evaluate the systemic toxicity of drug and cosmetic compounds. As published and featured as a frontispiece in the prestigious peer-reviewed scientific journal Advanced Functional Materials, the microfluidic device with interlinking modules containing human-derived heart, liver, skeletal muscle and nervous system cells was able to maintain cellular viability and record cellular function in real-time for 28 days.

The University of Central Florida (UCF) in collaboration with the Florida biotech firm Hesperos, Inc., has shown that one of its innovative four-organ in vitro (out of body) model systems is able to realistically replicate in vivo (in body) responses to sustained drug dosing of human cells.

“The technology could allow us, in the very near future, to move chronic drug experiments from animal models to these novel human in vitro models,” said Hesperos Chief Scientist James J. Hickman, who is a Professor at UCF’s NanoScience Technology Center.

A new nanomaterial developed by scientists at the University of Bath could solve a conundrum faced by scientists probing some of the most promising types of future pharmaceuticals.

Scientists who study the nanoscale—with molecules and materials 10,000 smaller than a pinhead—need to be able to test the way that some molecules twist, known as their chirality, because mirror image molecules with the same structure can have very different properties. For instance one kind of molecule smells of lemons when it twists in one direction, and oranges when twisted the other way.

Detecting these twists is especially important in some high-value industries such as pharmaceuticals, perfumes, food additives and pesticides.

Charge density fluctuations are observed in all families of high-critical temperature (Tc) superconducting cuprates. Although constantly found in the underdoped region of the phase diagram at relatively low temperatures, physicists are unclear how the substrates influence unusual properties of these systems. In a new study now published on Science, R. Arpaia and co-workers in the departments of microtechnology and nanoscience, the European Synchrotron, and quantum device physics in Italy, Sweden and France used resonant X-ray scattering to carefully determine the charge density modulations in Yttrium Barium Copper Oxide (YBa₂Cu₃O_{7– ẟ}) and Neodymium Barium Copper Oxide (Nd_1+x Ba_2–x Cu₃O_7–ẟ) for several doping levels. The research team isolated short-range dynamic charge density fluctuations (CDFs) in addition to the previously known quasi-critical charge density waves (CDW). The results persisted well above the pseudo-gap temperature T*, which they characterized by a few milli-electron volts (meV) to spread across a large area of the phase diagram.

Cuprate high temperature superconductors (HTS) are different from the Landau Fermi liquid paradigm due to quasi-two dimensionality (2-D) of their layered structure and large electron-electron repulsion. During optimal doping and the pseudo gap state (states at which less than optimal current carrier concentrations result in anomalous electronic properties), short to medium-range charge density wave order can emerge to weakly compete with superconductivity. Physicists first developed theoretical proposals of CDW and low energy charge fluctuations after first discovering HTS. Subsequently, they developed experimental evidence in selective materials and in all cuprate families. Researchers had observed long-range tridimensional CDW (3D CDW) order inside the superconductivity dome within high magnetic fields that weaken superconductivity or in epitaxially grown (deposition of a crystalline layer on a crystalline substrate) samples.

With apologies to “Spinal Tap,” it appears that black can, indeed, get more black.

MIT engineers report today that they have cooked up a material that is 10 times blacker than anything that has previously been reported. The material is made from vertically aligned carbon nanotubes, or CNTs—microscopic filaments of carbon, like a fuzzy forest of tiny trees, that the team grew on a surface of chlorine-etched aluminum foil. The foil captures more than 99.96 percent of any incoming light, making it the blackest material on record.

The researchers have published their findings today in the journal ACS-Applied Materials and Interfaces. They are also showcasing the cloak-like material as part of a new exhibit today at the New York Stock Exchange, titled “The Redemption of Vanity.”

A newly developed type of architected metamaterial has the ability to change shape in a tunable fashion.

While most reconfigurable materials can toggle between two distinct states, the way a switch toggles on or off, the new material’s shape can be finely tuned, adjusting its physical properties as desired. The material, which has potential applications in next-generation energy storage and bio-implantable micro-devices, was developed by a joint Caltech-Georgia Tech-ETH Zurich team in the lab of Julia R. Greer.

Greer, the Ruben F. and Donna Mettler Professor of Materials Science, Mechanics and Medical Engineering in Caltech’s Division of Engineering and Applied Science, creates materials out of micro- and nanoscale building blocks that are arranged into sophisticated architectures that can be periodic, like a lattice, or non-periodic in a tailor-made fashion, giving them unusual physical properties.

A startup that spun out of Cambridge University claims a battery breakthrough that can charge an electric car in just six minutes.

It’s something we heard before, but the difference here is that they claim that they can commercialize the new battery as soon as next year.

The startup, Echion Technologies, was founded by Dr. Jean De La Verpilliere while he was studying for his PhD in nanoscience at the University of Cambridge.